Group One Trading LLC Has $53,000 Holdings in Enovis Corporation $ENOV

Group One Trading LLC lessened its stake in Enovis Corporation (NYSE:ENOV) by 92.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,334 shares of the company’s stock after selling 27,779 shares during the quarter. Group One Trading LLC’s holdings in Enovis were worth $53,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of Enovis in the 3rd quarter valued at about $83,435,000. River Road Asset Management LLC grew its holdings in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares during the period. Paradigm Capital Management Inc. NY grew its holdings in Enovis by 41.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after purchasing an additional 326,900 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after purchasing an additional 287,687 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders purchased 4,200 shares of company stock valued at $92,084. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ENOV shares. Zacks Research lowered shares of Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. Evercore set a $32.00 price target on Enovis in a research report on Monday, July 6th. Wells Fargo & Company cut their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and a consensus target price of $41.71.

Enovis Stock Down 1.6%

Shares of ENOV stock opened at $26.12 on Friday. The firm’s fifty day moving average price is $23.60 and its two-hundred day moving average price is $23.76. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. Enovis Corporation has a 1 year low of $19.14 and a 1 year high of $34.28. The firm has a market capitalization of $1.50 billion, a P/E ratio of -1.31 and a beta of 1.39.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.